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Objective: In this study we aim to assess the cost-effectiveness analysis of minimally
invasive vein harvesting. The great saphenous vein is the most commonly used
conduit in coronary artery bypass surgery. In the past decade minimally invasive tech-
niques have been developed to reduce the surgical trauma associated with the conven-
tional open vein-harvesting technique. There is strong evidence to suggest that
minimally invasive harvesting can reduce postoperative wound healing complica-
tions, pain, mobility restriction, and hospital stay. Despite the increasingly widespread
use of this technique, formal cost-effectiveness analysis has never been performed.
Methods: Economic analysis was performed according to the National Institute of
Healthcare and Clinical Excellence guidelines on the evaluation of technology by
using published data on postoperative pain and mobility restriction, locally collected
data, National Health Service reference costs, and manufacturer’s data. Probabilistic
sensitivity analysis was performed to investigate and quantify the uncertainty associ-
ated with the results of our analysis.
Results: The results of our analysis demonstrate that minimally invasive vein harvesting
was more cost-effective, with an incremental cost-effectiveness ratio of $19,858.87/
quality-adjusted life year (QALY), comparing favorably with other health care interven-
tions. Probabilistic sensitivity analysis demonstrated with 95.6% certainty that endo-
scopic harvesting was more cost-effective at a willingness-to-pay threshold of
$50,000/quality-adjusted life year. Alternative analysis suggested that even with con-
siderable uncertainty associated with quality of life after vein harvesting, minimally
invasive harvesting was more cost-effective than conventional vein harvesting.
Conclusion: Minimally invasive harvesting is the most cost-effective method of
harvesting the great saphenous vein and can significantly improve a patient’s quality
of life.
D
espite the increasing use of arterial conduits for coronary artery bypass sur-
gery, the great saphenous vein is still the most commonly used conduit. Har-
vesting of the saphenous vein for use as a conduit in bypass surgery by using
a conventional open vein-harvesting technique involves a large longitudinal incision
extending from the medial malleolus along the medial aspect of the knee and often to
the groin. Over the past decade, minimally invasive alternatives have been developed,
such as endoscopic vein harvesting,1-4 in which the vein is harvested through either 1
or 2 small transverse incisions above the knee, below the knee, or both, depending on
the length of conduit required.
The reduced surgical trauma resulting from the smaller incisions made during
minimally invasive harvesting has been shown to significantly reduce many of the
common complications of great saphenous vein harvesting. There is strong evidence
to suggest that wound infection rates after minimally invasive harvesting are
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health-related quality of life
HRQoL 5 health-related quality of life
ICER 5 incremental cost-effectiveness ratio
NHS 5 National Health Service
QALY 5 quality-adjusted life year
VAS 5 Visual Analog Scale
significantly less than those after conventional harvesting, as
are noninfective wound-healing complications, postopera-
tive pain and loss of mobility, readmission, and reinter-
vention.4-8 Patient satisfaction after minimally invasive
harvesting is significantly greater than that after conventional
harvesting.4-6 Furthermore, there is no significant difference
in conduit quality when assessed either histologically, macro-
scopically, or according to clinical outcomes.4-6,9
Despite the popularity and strong evidence demonstrating
the clinical effectiveness of minimally invasive harvesting,4-9
formal cost-effectiveness analysis of the alternative tech-
niques for harvesting the great saphenous vein has not been
previously performed. This is important because unless the
increased clinical effectiveness of an intervention justifies
its incremental cost, policymakers cannot justify allocating
resources for its widespread adoption.10,11
Consequently, the specific aims of this study are as fol-
lows: (1) to investigate health-related quality of life (HRQoL)
after minimally invasive and conventional harvesting of the
great saphenous vein for coronary artery bypass surgery;
(2) to compare the cost-effectiveness of the minimally inva-
sive and endoscopic vein-harvesting techniques; and (3) to
investigate and quantify the uncertainty associated with the
results of our analysis.Figure 1. Summary of the decision–analytic
model used and the sources of model parameters.
EQ-5D, EuroQol 5-dimension measure of health-
related quality of life; HRQoL, health-related qual-
ity of life; QALY, quality-adjusted life year; ICER,
incremental cost-effectiveness ratio.810 The Journal of Thoracic and Cardiovascular Surgery c AprTo investigate the cost-effectiveness of minimally inva-
sive vein harvesting, we constructed a decision-analytic
model. We used published data on postoperative pain and
mobility restriction12 to calculate the HRQoL associated
with each vein-harvesting technique.10,13 We used data on
the length of the operative procedure and hospital stay,5,8
locally collected cost data, National Health Service (NHS)
reference costs,14 and manufacturer’s data to calculate the in-
cremental cost associated with minimally invasive vein har-
vesting. Probabilistic sensitivity analysis was performed to
investigate and quantify the uncertainty associated with the
results of our analysis.10
Materials and Methods
Cost-effectiveness analysis was performed from a UK NHS per-
spective according to National Institute of Healthcare and Clinical
Excellence guidelines on the assessment of new technology.11
Costs are reported in US dollars (an exchange rate of $1.98 to 1
UK Pound Sterling was used). The effects of the interventions on
HRQoL were measured in quality-adjusted life years (QALYs).
Cost-effectiveness ratios are reported in dollars per QALY. Because
all capital expenditure and effects occurred within 6 weeks of the
primary procedure in our analysis, cost and effects were not
discounted. Probabilistic sensitivity analysis was performed to in-
vestigate and quantify the uncertainty associated with the results
of our analysis.10 Our analysis is summarized in Figure 1. A full
list of all model parameters is given in Table 1. Analysis was per-
formed with decision-analytic software (TreeAge-Pro; TreeAge,
Williamstown, Mass).
Calculation of Incremental Effects
Despite evidence showing that postoperative pain, mobility, and pa-
tient satisfaction are improved after minimally invasive vein harvest-
ing,4,6 an improvement in HRQoL has not been demonstrated after
minimally invasive harvesting compared with that after conventional
harvesting. Capturing short-term HRQoL benefits after surgical inter-
vention is problematic, and neither of the studies that attempted toil 2008
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PTABLE 1. Summary of parameters used in the decision analytical model
Model parameter (source of parameter estimate) Value Distribution Range/SD
Incremental costs
Cost parameters ($)
Cost of disposable endoscopic equipment (manufacturer) 742.50 Triangular 659.99–825.01
Cost of a cardiothoracic bed day14 613.80 Triangular 257.40–902.88
Cost of a minute of cardiothoracic theater time (locally collected data) 21.78 Triangular 10.89–32.67
Model parameters
Incremental operative time for minimally invasive vein harvesting (min)5 15.26 Triangular 0.01–30.51
Incremental hospital stay of conventional vein harvesting (d)8 1.04 Triangular 0.16–1.92
Incremental effects
Likert Visual Analogue Score12
Pain at discharge
Minimally invasive vein harvesting 1.1 Normal 2
Conventional vein harvesting 4.7 Normal 1.8
Pain at 6 wk
Minimally invasive vein harvesting 0.9 Normal 2.4
Conventional vein harvesting 1.5 Normal 2.4
Mobility at discharge
Minimally invasive vein harvesting 8.8 Normal 0.8
Conventional vein harvesting 6.4 Normal 1.3
Mobility at 6 wk
Minimally invasive vein harvesting 9.8 Normal 0.5
Conventional vein harvesting 7 Normal 3.5
HRQoL (utility [calculated])
At discharge
Minimally invasive vein harvesting 0.9443
Conventional vein harvesting 0.6815
At 6 wk
Minimally invasive vein harvesting 0.9599
Conventional vein harvesting 0.8219
QALY (payoff [calculated])
Base case
Minimally invasive vein harvesting 0.1099 Triangular 0.0989–0.1208
Conventional vein harvesting 0.0867 Triangular 0.0781–0.0954
Alternative analysis 1
Minimally invasive vein harvesting 0.1099 Triangular 0.0879–0.1318
Conventional vein harvesting 0.0867 Triangular 0.0694–0.1041
Alternative analysis 2
Minimally invasive vein harvesting 0.1099 Triangular 0.0769–0.1428
Conventional vein harvesting 0.0867 Triangular 0.0607–0.1128
SD, Standard deviation; HRQoL, health-related quality of life; QALY, quality-adjusted life years.quantify the benefits in HRQoL after minimally invasive harvesting
was designed with this aim.15,16 Consequently, we calculated HRQoL
for patients after vein harvesting by using published data on postoper-
ative pain and mobility.
Several authors have published data on pain or mobility after
vein harvesting; however, few authors have published information
on both from the same population.12,15-20 To calculate postoperative
utility, we chose to use estimates from Kiaii and colleagues12 for 3
reasons: (1) it is a recent study; (2) this study is a prospective, ran-
domized controlled trial; and (3) in this study the authors used the
same method for quantifying postoperative mobility restriction
and pain, a Likert Visual Analogue Scale (VAS). Assuming that
VAS scores were normally distributed, the mean and standard devi-
ation VAS scores at discharge and 6 weeks postoperatively wereThe Journal of Thoraconverted to a set of discrete scores between 0 and 3. These values
were then multiplied by the coefficients for Time Trade-Off tariffs
according to the EuroQol Group’s EuroQol 5-dimension measure
of health-related quality of life (EQ-5D) formula to convert them
into utility scores.13
In doing so, we made assumptions that biased our analysis
against minimally invasive vein harvesting. Because data were
only available for 2 of the 5 EQ-5D dimensions (ie, Mobility and
Pain/discomfort), we assumed that the other 3 dimensions (ie,
Self-care, Usual activity, and Anxiety/depression) had the same
values after both techniques. In doing so, we probably underesti-
mated the HRQoL (utility) after minimally invasive harvesting
and thus biased our analysis in favor of conventional harvesting.
Although it is possible to experience severe pain without havingcic and Cardiovascular Surgery c Volume 135, Number 4 811
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those patients who had the most severe pain experienced the most
significant restriction in mobility. This resulted in smaller estimates
of the reduction in utility after vein harvesting, potentially biasing
our analysis in favor of conventional harvesting. The calculated
reductions in utility after vein harvesting at discharge and 6 weeks
postoperatively are shown in Table 1.
To calculate the incremental QALY associated with minimally
invasive vein harvesting, we assumed that recovery of mobility
and reduction in pain were constant after both techniques between
discharge and 6 weeks. We also assumed that recovery of mobility
and cessation of wound-related pain were complete after 6 weeks.
Because more patients continued to experience pain and mobility
restriction after conventional harvest at 6 weeks, the assumption
that recovery was complete after 6 weeks might also bias our anal-
ysis in favor of the conventional vein-harvesting technique. Finally,
we did not account for differences in utility before discharge when
calculating QALYs. As calculated, utility was better after minimally
invasive harvesting at discharge, which might also bias our analysis
in favor of conventional harvesting. Our method for calculating the
incremental QALY payoff is demonstrated in Figure 2.
Calculation of Incremental Costs
Several factors were identified that could account for a difference in
cost between minimally invasive and conventional vein harvesting:
the length of the procedure, the length of the hospital stay postoper-
atively, the additional cost of equipment used during minimally
invasive harvesting, the cost of treating the complications of the
vein-harvesting procedure, and the cost of reintervention as a result
of poor conduit quality.
Because there were no data available on the costs associated with
the cost of treating the complications of vein harvesting, these costs
were not formally included in our analysis, although they are, in
part, accounted for in the length of hospital stay. By not formally
accounting for the cost of the complications of vein harvesting,
we are further biasing our analysis toward conventional harvesting,
after which almost all complications are significantly more com-
mon.4-9 Similarly, we did not account for the cost of conduit failure
causing a subsequent cardiac event because there is no evidence that
harvesting technique affects conduit quality in cardiothoracic
surgery.4,6
Estimates of the incremental cost associated with the equipment
used in minimally invasive vein harvesting were based on the cost
of disposable equipment used in endoscopic vein harvesting
obtained from the manufacturer (Ethicon Vein Harvest System;812 The Journal of Thoracic and Cardiovascular Surgery c AprEthicon Endo-Surgery, Johnson & Johnson Medical Ltd, Ascot,
United Kingdom) for several reasons. First, because it is the most
technologically advanced method of minimally invasive vein har-
vesting, endoscopic harvesting is also the most expensive. Second,
by choosing the most expensive minimally invasive technique, we
have avoided biasing our analysis in favor of minimally invasive
harvesting. Furthermore, although there is insufficient evidence
comparing endoscopic and nonendoscopic minimally invasive vein
harvesting, endoscopic vein harvesting offers theoretic benefits over
other minimally invasive techniques, such as reduced traction and
direct visualization of the conduit during endoscopic harvesting,
which could result in better conduit quality and also better control
and visualization of bleeding points, reducing the degree of subcu-
taneous hematoma.4 Because our estimates and assumptions on
the efficacy of minimally invasive vein harvesting are based on
a group of patients among whom some underwent endoscopic vein
harvesting,4-9,12 if we did not account for the incremental cost of en-
doscopic harvesting, we could bias our analysis in favor of mini-
mally invasive vein harvesting. Finally, we chose to base our
costs on the Ethicon Vein Harvest System because it is one of the
more widely used commercially available vein-harvest systems.
Differences in the operative time and the hospital stay were
obtained from meta-analysis.5,8 The cost of a bed day was obtained
from 2005 NHS reference costs.14 The cost of a minute of cardiotho-
racic theater time was calculated by using routinely collected local
data according to the NHS manual.21 Our institution has higher
estate and staffing costs than the national average.21 Consequently,
the figure that we have used for the cost of 1 minute of elective car-
diothoracic theater time is probably higher than the national average.
Because minimally invasive harvesting takes longer than conven-
tional vein harvesting, the use of locally collected data probably
slightly biases our analysis against minimally invasive vein harvest-
ing.
A summary of all of the cost parameters used in our model can be
seen in Table 1.
Sensitivity Analysis
There is an element of uncertainty associated with all attempts to
consider the implications of health care interventions.10 Probabilis-
tic analysis was performed to examine the combined effect of model
parameter uncertainty by using Monte Carlo simulation,10 with
10,000 model recalculations. Parameters were sampled from the
distributions described in Table 1.
The confidence intervals obtained from meta-analyses5,8 were
used as the maximum and minimum values used to define triangularFigure 2. Plot of utility versus time after minimally
invasive endoscopic vein harvesting (EVH) and
conventional open vein harvesting (OVH). The
area between the plotted graphs represents the
incremental quality-adjusted life year (QALY)
payoff. HRQoL, Health-related quality of life.il 2008
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uncertainty associated with increased stay in the hospital after
conventional harvesting and increased operative time for minimally
invasive vein harvesting. The maximum and minimum values
associated with the cost of a cardiothoracic bed day were calculated
by doubling the difference between the mean and upper and lower
quartiles obtained from 2005 NHS reference costs.12 No data were
available on the uncertainty associated with the true value of
a cost of 1 minute of elective cardiothoracic theater time, and conse-
quently, confidence intervals of 650% were arbitrarily chosen that
mirrored the high degree of uncertainty associated with locally
collected data. The maximum and minimum values for the cost of
the disposable endoscopic equipment was obtained from the manu-
facturer (Ethicon Vein Harvest System, Ethicon Endo-Surgery, J&J
Medical Ltd) and reflects differences in the cost of the kit depending
on the size and specification of the equipment that the surgeon choo-
ses to use for each case. To reflect the uncertainty associated with
our estimates of the QALY payoffs, because of our unvalidated
method for calculating utilities, confidence intervals for the
QALY payoffs of 610% were used to define maximum and mini-
mum values used to define triangular distributions for probabilistic
sensitivity analysis.
Alternative analysis was also performed to further investi-
gate the uncertainty associated with our estimates of QALY
payoffs, with larger confidence intervals of 630% (alternative
analysis 1) and 650% assigned to the QALY payoffs (alterna-
tive analysis 2).
Results
HRQoL
We calculated the HRQoL (utility) at discharge to be 0.9443
after minimally invasive harvesting and 0.6815 after conven-
tional vein harvesting. Six weeks postoperatively, the utility
was 0.9599 after minimally invasive harvesting and 0.8219
after conventional vein harvesting. The QALY payoff after
minimally invasive and conventional vein harvesting over
a 6-week period was 0.1099 and 0.0867 QALY, respec-
tively.
Cost-effectiveness
The incremental cost of minimally invasive harvesting com-
pared with conventional vein harvesting was $458.74 (stan-
dard deviation, $304.15), and the incremental effect was
0.0231 QALY (standard deviation, 0.0057 QALY). This
represents an incremental cost-effectiveness ratio (ICER) of
$19,858.87/QALY.
Sensitivity Analysis
The effect of probabilistic sensitivity analysis is shown in the
ICER scatter plot in Figure 3. The ellipse encloses 95% of the
model recalculations; the dotted-diagonal line represents the
cost-effectiveness threshold, plotted at $50,000/QALY,
which is commonly applied in the published literature. In
4.4% of model recalculations, minimally invasive harvesting
is both more effective and less costly; in 91.2% of model
recalculations, endoscopic vein harvesting is more effectiveThe Journal of Thoraand more expensive but lies below the threshold. Conse-
quently, our sensitivity analysis shows that minimally inva-
sive harvesting is cost-effective, with 95.6% certainty at
a threshold of $50,000/QALY in our base case (Figure 4).
In the alternative analysis the ICER remained unchanged;
however, minimally invasive harvesting is only cost-
effective at $50,000/QALY, with a certainty of 77.1% in
alternative analysis 1 and 67.6% in alternative analysis 2
(Figure 4).
Discussion
We estimated the HRQoL (utility) on discharge to be 0.9443
after minimally invasive harvesting and 0.6815 after conven-
tional vein harvesting. Six weeks postoperatively, the utility
was 0.9599 after minimally invasive harvesting and 0.8219
after conventional vein harvesting. By using these calculated
utility estimates, we suggest that minimally invasive vein
harvesting is a cost-effective alternative to conventional
vein-harvesting techniques. The ICER of $19,858.87/
QALY compares favorably with other health care interven-
tions. Probabilistic sensitivity analysis demonstrated with
a 95.6% certainty that minimally invasive vein harvesting
was the most cost-effective technique at a cost-effectiveness
threshold of $50,000/QALY. Alternative analysis demon-
strated that even with a high degree of uncertainty associated
with the true value of the incremental QALY payoff
(650%), minimally invasive vein harvesting was more
cost-effective than conventional vein harvesting, with a cer-
tainty of 67.6%.
The effectiveness data were of a high quality, being either
from prospective randomized controlled trials12 or meta-
analyses.5,8 The cost data were current and relevant to our
analytic perspective. We performed probabilistic sensitivity
analysis and alternative analysis to fully investigate and
quantify the results of our cost-utility analysis. Arguably,
however, our estimates of the superior cost-effectiveness of
minimally invasive harvesting are conservative. Subgroup
analysis was not performed for high-risk patient groups,
such as women, the obese, and diabetics, because sufficient
data were not available.5 There is, however, strong evidence
to suggest that wound infection is significantly more com-
mon in these high-risk groups after conventional vein
harvesting compared with that after minimally invasive
vein harvesting,22 suggesting that minimally invasive vein
harvesting might be even more cost-effective in these high-
risk groups. Furthermore, as minimally invasive vein har-
vesting becomes more widely adopted, it is possible that
the costs associated with the equipment will be reduced,
increasing the cost-effectiveness of minimally invasive vein
harvesting. Our analysis did not take into account the costs
associated with the treatment of the complications of vein
harvesting because most complications are more common
after conventional harvesting compared with those after min-
imally invasive harvesting4-8; this might have further biasedcic and Cardiovascular Surgery c Volume 135, Number 4 813
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scatter plot. Each of the 10,000 plots represents
the incremental cost-effectiveness ratio of 1
model recalculation. The ellipse demonstrates
the 95% confidence interval of the mean incre-
mental cost-effectiveness ratio, enclosing 95%
of model recalculations. The diagonal dashed
line represents a cost-effectiveness threshold
plotted at $50,000/quality-adjusted life year
(QALY).our analysis in favor of conventional vein harvesting. Our use
of equipment costs associated with endoscopic vein harvest-
ing equipment in addition to many of the assumptions that we
made when calculating the effect on HRQoL probably
reduced our estimates of the superior cost-effectiveness of
minimally invasive harvesting even further. In the context
of these assumptions, which bias our analysis in favor of con-
ventional vein harvesting, and the results of our analysis,
which demonstrate with a high degree of certainty that min-
imally invasive vein harvesting is the most cost-effective
intervention, our study represents, for the first time in the
literature, a robust demonstration of the cost-effectiveness
of minimally invasive vein harvesting.
Implications for Practice
Despite considerable data suggesting that minimally invasive
vein harvesting is more effective in reducing the morbidity814 The Journal of Thoracic and Cardiovascular Surgery c Apassociated with vein harvesting5-9 and the increasingly com-
mon use of the minimally invasive vein-harvesting tech-
niques,6 the cost-effectiveness of minimally invasive vein
harvesting needed to be clarified. The finding that minimally
invasive vein harvesting is cost-effective is important for
several reasons. First, the great saphenous vein is the most
frequently used conduit during this commonly performed
operation,1,23 and there is considerable morbidity associated
with harvesting of the great saphenous vein.12,15-20 Further-
more, unless the increased clinical effectiveness of an inter-
vention can be shown to justify its incremental cost, then
policymakers have no incentive to allocate resources for its
widespread adoption.10,11 Finally, minimally invasive con-
duit harvesting techniques have the potential to be more
widely applied. The radial artery, for example, can be also
harvested by using minimally invasive techniques for use
as a conduit in coronary artery bypass surgery,4 and theFigure 4. Cost-effectiveness acceptability curve
showing the certainty with which minimally inva-
sive vein harvesting is most cost-effective at dif-
ferent willingness-to-pay thresholds (dollars per
quality-adjusted life year [$/QALY]) for the base
case and the alternative analyses.ril 2008
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ing techniques are being explored in vascular surgery, al-
though the efficacy is more controversial than in coronary
surgery for a number of reasons.24,25 Further research needs
to be focused on evaluating the effect of minimally invasive
harvesting on the patient’s quality of life.
Study Limitations
Because data were not available on HRQoL after harvesting
of the great saphenous vein, we synthesized utility values
from data on postoperative mobility and pain by using the
EQ-5D scoring system. Although every attempt was made
to ensure that all assumptions we made while doing this fa-
vored conventional vein harvesting, this method for calculat-
ing utility values is unvalidated.
Furthermore, we failed to quantify the cost of the learning
curve associated with minimally invasive vein harvesting,
which has been estimated to be as many as 20 cases,25 or to
perform formal NHS budget-effect analysis, which could be
as much as $12 million in the United Kingdom, where approx-
imately 25,000 bypass operations are performed annually.23
Conclusions
The results of our study, despite its limitations, represent
strong evidence for the cost-effectiveness of minimally inva-
sive vein harvesting compared with conventional harvesting
of the great saphenous vein. This is an important addition to
the considerable body of evidence suggesting that minimally
invasive vein harvesting has an important role in coronary
surgery. Minimally invasive harvesting techniques represent
effective technology that should be considered for wider
adoption to enhance the clinical and economic effectiveness
of coronary bypass surgery.
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